Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that will focus on developing a ...

Astellas Pharma (OTCPK:ALPMY) and YASKAWA Electric signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform utilizing the ...

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering ...

Yaskawa Electric's stock has underperformed due to ongoing destocking in automation and macroeconomic uncertainties, but shares are now relatively inexpensive, making it a potential recovery play.

YASKAWA Electric Co. (OTCMKTS:YASKY – Get Free Report) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 16,100 shares ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Based on the memorandum of agreement signed in May, 2024, Astellas and YASKAWA have been advancing discussions toward establishing a joint venture to leverage their mutual strengths and accelerate ...

(RTTNews) - Japan's Astellas Pharma Inc. (ALPMY, ALPMY) announced that it has signed a definitive agreement with YASKAWA Electric Corp. to establish a joint venture for the development of a cell ...

Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that will focus on developing a cell therapy product manufacturing platform. The JV will leverage a ...